Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AOXG NASDAQ:CMMB NASDAQ:CYCC NYSEMKT:PHGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.01+25.0%$0.01$0.00▼$0.02$1.52M7.0552,690 shs150,155 shsCMMBChemomab Therapeutics$3.28-2.7%$3.21$2.39▼$9.84$16.97M0.57234,758 shs332,177 shsCYCCCyclacel Pharmaceuticals$6.44-4.9%$7.30$3.08▼$597.60$14.43M0.1582,670 shs220,161 shsPHGEBiomX$0.58-21.9%$0.52$0.34▼$2.40$15.11M1.45347,190 shs53,300 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical+25.00%-48.98%-16.67%-28.57%-70.93%CMMBChemomab Therapeutics-2.67%+20.59%+9.70%-29.08%-36.43%CYCCCyclacel Pharmaceuticals0.00%0.00%-4.87%+73.58%-96.50%PHGEBiomX-6.18%+12.04%+24.89%+37.71%-40.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.01+25.0%$0.01$0.00▼$0.02$1.52M7.0552,690 shs150,155 shsCMMBChemomab Therapeutics$3.28-2.7%$3.21$2.39▼$9.84$16.97M0.57234,758 shs332,177 shsCYCCCyclacel Pharmaceuticals$6.44-4.9%$7.30$3.08▼$597.60$14.43M0.1582,670 shs220,161 shsPHGEBiomX$0.58-21.9%$0.52$0.34▼$2.40$15.11M1.45347,190 shs53,300 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical+25.00%-48.98%-16.67%-28.57%-70.93%CMMBChemomab Therapeutics-2.67%+20.59%+9.70%-29.08%-36.43%CYCCCyclacel Pharmaceuticals0.00%0.00%-4.87%+73.58%-96.50%PHGEBiomX-6.18%+12.04%+24.89%+37.71%-40.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAOXGAoxing Pharmaceutical 0.00N/AN/AN/ACMMBChemomab Therapeutics 2.33Hold$26.50707.93% UpsideCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/APHGEBiomX 3.00Buy$21.003,539.51% UpsideCurrent Analyst Ratings BreakdownLatest AOXG, CMMB, PHGE, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CMMBChemomab TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CMMBChemomab TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/27/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $25.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$2.87 per shareN/ACYCCCyclacel Pharmaceuticals$40K360.64N/AN/A($58.87) per share-0.11PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAOXGAoxing PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/ACMMBChemomab Therapeutics-$13.94M-$2.36N/AN/AN/AN/A-94.71%-76.53%11/13/2025 (Estimated)CYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-723.64%-145.51%11/10/2025 (Estimated)PHGEBiomX-$28.32M-$1.36N/AN/AN/AN/A-127.82%-56.50%N/ALatest AOXG, CMMB, PHGE, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CMMBChemomab Therapeutics-$0.80-$0.36+$0.44-$0.09N/AN/A8/13/2025Q2 2025CYCCCyclacel Pharmaceuticals-$72.00-$0.98+$71.02-$0.98$0.03 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAOXGAoxing PharmaceuticalN/AN/AN/ACMMBChemomab TherapeuticsN/A7.427.42CYCCCyclacel PharmaceuticalsN/A5.775.77PHGEBiomX0.512.842.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAOXGAoxing PharmaceuticalN/ACMMBChemomab Therapeutics46.05%CYCCCyclacel Pharmaceuticals23.58%PHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipAOXGAoxing Pharmaceutical17.80%CMMBChemomab Therapeutics11.91%CYCCCyclacel Pharmaceuticals51.20%PHGEBiomX3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableCMMBChemomab Therapeutics205.17 million4.56 millionNot OptionableCYCCCyclacel Pharmaceuticals142.24 million1.09 millionOptionablePHGEBiomX12026.56 million44.04 millionNot OptionableAOXG, CMMB, PHGE, and CYCC HeadlinesRecent News About These CompaniesBiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 4, 2025 | finance.yahoo.comBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic FibrosisAugust 19, 2025 | globenewswire.comBiomX Posts Q2 Loss With 14% Cost DropAugust 14, 2025 | aol.comABiomX Inc. (PHGE) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comBiomX Reports Second Quarter 2025 Financial Results and Provides Program UpdatesAugust 13, 2025 | globenewswire.comWhat to Expect from BiomX's EarningsAugust 12, 2025 | benzinga.comBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025August 6, 2025 | globenewswire.comBiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapyJuly 14, 2025 | investing.comBiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis TreatmentJuly 14, 2025 | msn.comPHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron'sJuly 14, 2025 | barrons.comBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic FibrosisJuly 14, 2025 | globenewswire.comBiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic FibrosisJuly 8, 2025 | globenewswire.comBiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 ConferenceMay 21, 2025 | nasdaq.comBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 ConferenceMay 19, 2025 | globenewswire.comBiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comBiomX Inc. (PHGE) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program UpdatesMay 15, 2025 | globenewswire.comBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025May 8, 2025 | globenewswire.comBiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 18, 2025 | zacks.comBiomX announces going concern qualification from independent auditApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAOXG, CMMB, PHGE, and CYCC Company DescriptionsAoxing Pharmaceutical OTCMKTS:AOXG$0.0050 +0.00 (+25.00%) As of 10/10/2025 03:37 PM EasternAoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Chemomab Therapeutics NASDAQ:CMMB$3.28 -0.09 (-2.67%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$3.30 +0.02 (+0.58%) As of 10/10/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Cyclacel Pharmaceuticals NASDAQ:CYCC$6.44 -0.33 (-4.87%) Closing price 09/11/2025Extended Trading$6.44 0.00 (0.00%) As of 09/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.BiomX NYSEMKT:PHGE$0.58 -0.16 (-21.92%) Closing price 10/10/2025 03:57 PM EasternExtended Trading$0.54 -0.03 (-5.89%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
